Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (21-30 of 187) with videos related to

Pageof 19
Sort By:
American Journal of Hematology|August 9, 2014
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term studyFrancesca Palandri, Nicola Polverelli, Lucia Catani, et al.
American Journal of Hematology|January 23, 2016
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 yearsFrancesca Palandri, Nicola Polverelli, Daria Sollazzo, et al.
Hematology Reports|July 25, 2012
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiencyFrancesca Palandri, Nicola Polverelli, Francesca Lifrieri, et al.
Cancers|June 22, 2023
Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP StudyFrancesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, et al.
Therapeutic Advances in Hematology|March 27, 2026
Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit controlClaire N Harrison, Jean-Jacques Kiladjian, J E Hamer-Maansson, et al.
Cancers|November 13, 2021
Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular DeterminantsElena Sabattini, Marco Pizzi, Claudio Agostinelli, et al.
Frontiers in Oncology|August 8, 2024
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectivesMassimo Breccia, Francesca Palandri, Nicola Polverelli, et al.
Experimental Hematology|January 8, 2011
The CD47 pathway is deregulated in human immune thrombocytopeniaLucia Catani, Daria Sollazzo, Francesca Ricci, et al.
Leukemia & Lymphoma|February 24, 2009
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patientsFrancesca Palandri, Emanuela Ottaviani, Federica Salmi, et al.
Hematology Reports|July 12, 2021
The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case reportGiuseppe Auteri, Daniela Bartoletti, Clara Bertuzzi, et al.
Pageof 19

Showing results (21-30 of 187) with videos related to

Sort By:
Pageof 19
American Journal of Hematology|August 9, 2014
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term studyFrancesca Palandri, Nicola Polverelli, Lucia Catani, et al.
American Journal of Hematology|January 23, 2016
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 yearsFrancesca Palandri, Nicola Polverelli, Daria Sollazzo, et al.
Hematology Reports|July 25, 2012
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiencyFrancesca Palandri, Nicola Polverelli, Francesca Lifrieri, et al.
Cancers|June 22, 2023
Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP StudyFrancesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, et al.
Therapeutic Advances in Hematology|March 27, 2026
Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit controlClaire N Harrison, Jean-Jacques Kiladjian, J E Hamer-Maansson, et al.
Cancers|November 13, 2021
Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular DeterminantsElena Sabattini, Marco Pizzi, Claudio Agostinelli, et al.
Frontiers in Oncology|August 8, 2024
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectivesMassimo Breccia, Francesca Palandri, Nicola Polverelli, et al.
Experimental Hematology|January 8, 2011
The CD47 pathway is deregulated in human immune thrombocytopeniaLucia Catani, Daria Sollazzo, Francesca Ricci, et al.
Leukemia & Lymphoma|February 24, 2009
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patientsFrancesca Palandri, Emanuela Ottaviani, Federica Salmi, et al.
Hematology Reports|July 12, 2021
The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case reportGiuseppe Auteri, Daniela Bartoletti, Clara Bertuzzi, et al.
Pageof 19